Current and emerging new treatment strategies for mantle cell lymphoma

References

• Campo E, Swerdlow SH, Harris NL, . The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Ferrer A, Salaverria I, Bosch F, . Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007;109: 2473–2480.
   PubMed Web of Science ®Google Scholar
• Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750–762.
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26–38.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Hoster E, Bea S, . Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk Lymphoma 2010;51:1612–1622.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Zettl A, Bea S, . Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216–1222.
   PubMed Web of Science ®Google Scholar
• Kridel R, Meissner B, Rogic S, . Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012;119:1963–1971.
   PubMed Web of Science ®Google Scholar
• Fernandez V, Salamero O, Espinet B, . Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Ek S, Dictor M, Jerkeman M, . Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008;111:800–805.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, . SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555–1562.
   PubMed Web of Science ®Google Scholar
• Schaffel R, Hedvat CV, Teruya-Feldstein J, . Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010;21:133–139.
   PubMed Web of Science ®Google Scholar
• Teodorovic I, Pittaluga S, Kluin-Nelemans JC, . Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995;13:2819–2826.
   PubMed Web of Science ®Google Scholar
• Argatoff LH, Connors JM, Klasa RJ, . Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067–2078.
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Pinotti G, . Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257–262.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Unterhalt M, Herrmann R, . Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998;16:1922–1930.
   PubMed Web of Science ®Google Scholar
• Herrmann A, Hoster E, Zwingers T, . Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511–518.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, . Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27: 1209–1213.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, . High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, Feng L, . Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010;150:200–208.
   PubMed Web of Science ®Google Scholar
• Epner EM, Unger J, Miller T, . A multi center trial of hyperCVAD+ rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007;110(Suppl. 1): Abstract 387.
   PubMed Web of Science ®Google Scholar
• Andersen NS, Pedersen L, Elonen E, . Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003;71:73–80.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, . Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Suzan F, . Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587–593.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Levy V, . Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004;89:1275–1276.
   PubMed Web of Science ®Google Scholar
• Delarue R, Haioun C, Ribrag V, . RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA. Blood 2008;112(Suppl. 1): Abstract 581.
   Google Scholar
• Hermine O, Hoster E, Walewski J, . Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2010;116(Suppl. 1): Abstract 110.
   Google Scholar
• LaCasce AS, Vandergrift JL, Rodriguez MA, . Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012;119:2093–2099.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans JC, Hoster E, Walewski J, . R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma. Blood 2011;118(Suppl. 1): Abstract 439.
   Google Scholar
• Kahl BS, Longo WL, Eickhoff JC, . Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418–1423.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP, . Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106–114.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L, . Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26:204–210.
   PubMed Web of Science ®Google Scholar
• Roue G, Lopez-Guerra M, Milpied P, . Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008; 14:6907–6915.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Heine K, Bodenstein H, . Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients. J Clin Oncol 2008;26(Suppl.): Abstract 8572.
   Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, . Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
   Google Scholar
• Jerkeman M, Kolstad A, Laurell A, . Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. Blood 2011;118(Suppl. 1): Abstract 2700.
   Google Scholar
• Magni M, Di Nicola M, Carlo-Stella C, . Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: a multicenter study. Blood 2011;118(Suppl. 1): Abstract 1647.
   PubMed Web of Science ®Google Scholar
• Visco C, Zambello R, Paolini R, . Rituximab, bendamustine and cytarabine (R-BAC) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant. Blood 2011;118(Suppl. 1): Abstract 2677.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti S, . Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23:705–711.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, . Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, . Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520–525.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Wright J, Moskowitz C, . Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676–684.
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, . Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667–675.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Furman RR, . Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Li H, Smith MR, . The VcR-CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405 - a phase II study of VcR-CVAD with maintenance rituximab for MCL. Blood 2009;114(Suppl. 1): Abstract 1661.
   Google Scholar
• Perez-Galan P, Mora-Jensen H, Weniger MA, . Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011;117:542–552.
   PubMed Web of Science ®Google Scholar
• Peponi E, Drakos E, Reyes G, . Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006;169:2171–2180.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Ghobrial I, . Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347–5356.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Inwards DJ, Rowland KM Jr, . Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113: 508–514.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, . Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Tang H, Kurtin PJ, . Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011;12:361–368.
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH, . Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
   PubMed Web of Science ®Google Scholar
• Warsch S, Hosein PJ, Maeda LS, . A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 2012;53:1299–1305.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL, . The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807–2812.
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, . Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69:7347–7356.
   PubMed Web of Science ®Google Scholar
• Gaidarova S, Corral LG, Glezer E, . Treatment of MCL cells with combined rituximab and lenalidomide enhances NK-mediated synapse formation and cell killing. Blood 2009;114(Suppl. 1): Abstract 1687.
   Google Scholar
• Habermann TM, Lossos IS, Justice G, . Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344–349.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, . An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Zaja F, De Luca S, Vitolo U, . Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012;97:416–422.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang L, Fayad L, . Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 2008;112(Suppl. 1): Abstract 3058.
   Google Scholar
• Robinson SP, Schmitz N, Taghipour G, . Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant related mortality and a poor outcome in patients with chemoresistant disease. Blood 2004; 104(Suppl. 1): Abstract 2260.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Lee MS, Saliba RM, . Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003;21:4407–4412.
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, . CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Kahl B, Byrd JC, Flinn IW, . Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010;116(Suppl. 1): Abstract 1777.
   PubMed Web of Science ®Google Scholar
• Garlich JR, Becker MD, Shelton CF, . Phase I study of novel prodrug dual PI3K/mTOR inhibitor SF1126 in B-cell malignancies. Blood 2010;116(Suppl. 1): Abstract 1783.
   Google Scholar
• Friedman DR, Davis PH, Lanasa MC, . Pre-clinical and interim results of a phase II trial of perifosine in patients with relapsed or refractory chronic Lymphocytic leukemia (CLL). Blood 2010;116(Suppl. 1): Abstract 1842.
   Google Scholar
• Gills JJ, Dennis PA: Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102–110.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Popplewell L, Winter JN, . PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib. Blood 2010;116(Suppl. 1): Abstract 3963.
   Google Scholar
• Renner C, Zinzani P, Gressin R, . A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012;97:1085–1091.
   PubMed Web of Science ®Google Scholar
• Gupta M, Hendrickson AW, Han JJ, . Dual inhibition of mTORC1/mTORC2 induces apoptosis of mantle cell lymphoma by preventing Rictor mediated AKTS473 phosphorylation by potentiating AKT2-PHLPP1 association. Blood 2010;116(Suppl. 1): Abstract 772.
   Google Scholar
• Boyd RS, Jukes-Jones R, Walewska R, . Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics 2009;8:1501–1515.
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M, . Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132:303–316.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, . Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578–2585.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Seymour JF, Kluin-Nelemans HC, . A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19: 247–253.
   PubMed Web of Science ®Google Scholar
• Fowler N, Sharman JP, Smith SM, . The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. Blood 2010;116(Suppl. 1): Abstract 964.
   PubMed Web of Science ®Google Scholar
• Wang L, Martin P, Blum KA, . The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 2011;118(Suppl. 1): Abstract 442.
   Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547–566.
   PubMed Web of Science ®Google Scholar
• Kouroukis CT, Belch A, Crump M, . Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:1740–1745.
   PubMed Web of Science ®Google Scholar
• Lin TS, Blum KA, Fischer DB, . Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010;28:418–423.
   PubMed Web of Science ®Google Scholar
• Manohar SM, Rathos MJ, Sonawane V, . Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res 2011;35:821–830.
   PubMed Web of Science ®Google Scholar
• Santo L, Vallet S, Hideshima T, . AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010;29:2325–2336.
   PubMed Web of Science ®Google Scholar
• Squires MS, Cooke L, Lock V, . AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther 2010;9: 920–928.
   PubMed Web of Science ®Google Scholar
• Marzec M, Kasprzycka M, Lai R, . Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006;108: 1744–1750.
   PubMed Web of Science ®Google Scholar
• Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008;33:122–131.
   PubMed Web of Science ®Google Scholar
• Howard OM, Gribben JG, Neuberg DS, . Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288–1294.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, . Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Smith MR, Li H, Gordon L, . Phase II study of R-CHOP followed by (90)Y-ibritumomab tiuxetan in untreated mantle cell lymphoma (MCL): 5 year follow-up of Eastern Cooperative Oncology Group E1499. Ann Oncol 2011; 22:86–87.
   PubMed Web of Science ®Google Scholar
• Herold M, Dolken G, Fiedler F, . Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol 2003;82:77–79.
   PubMed Web of Science ®Google Scholar
• Younes A, Fanale MA, McLaughlin P, . Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. Blood 2010;116(Suppl. 1): Abstract 2830.
   Google Scholar